A. Normal Urinary Bladder Function [1]
- Detrusor muscle provides contractile force for emptying urinary bladder
- Detrusor muslce receives parasympathetic innervation via S2-S4 spinal nerves
- Internal Urinary Sphincter
- Derived from bladder muscle layer beginning in urinary trigone
- Involuntary muscle innervated by motor fibers from T11-L2 (sympathetic system)
- alpha-1-adrenergic receptors regulate contraction
- External urethral sphincter and perineal muscles are voluntary from pudendal nerves
- Normal adult bladder holds about 400mL (13.5 ounces) without overdistension
- Sensations of fullness are neurally transmitted above this volume
- Transmission to spinal cord via alpha myelinated bladder afferents
- Sacral spinal cord relaxes sphincters above this volume unless cortical override occurs
- The pontine micturition area is the initial brain area involved
- Pontine CNS Control of Micturition
- Pontine signals permit one to voluntarily delay bladder emptying
- Two main signals are involved: detrusor relaxation and bladder outlet constriction
- Detrusor relaxation mediated through ß2-adrenergic receptors in bladder body
- alpha1-adrenergic stimulation leads to bladder neck constriction
- Pelvic floor muscles also constrict, preventing urinary leakage
- Hypogastric and pudendal nerves carry these inhibitory signals
- These are sympathetic nerves, which also block parasympathetic pelvic signals
- Bladder Emptying
- In appropriate circumstance, CNS releases inhibitory signals, allow bladder emptyping
- Normal emptying involves coordination of multiple systems
- Relaxation of bladder outlet, increase detrusor pressure, relax external sphincter
- Spinal cord injuries above S2 lead to spontaneous urination when bladder fills
B. Spastic Type
- Typically due to Upper Motor Neuron Dysfunction
- This leads to sphincter-detrusor dys-synergy
- This dys-synergy is uncoordinated sphincter-detrusor function
- Causes
- Multiple Sclerosis [1]
- Spinal Cord Damage
- Head Trauma
- Stroke
- Symptoms
- Frequent Reflex Voiding
- Small Volumes
- Urinary frequency with urgency
- "Urge inconcontinence"
- Rule out urinary tract infection (UTI)
- Treatment
- Medications: Muscarinic anti-cholinergics are first line
- Imipramine (Tofranil®), a tricyclic agent, may be helpful
- Other tricyclic antidepressant agents may be used but are not recommended
- Surgery: sphincterotomy
- Anti-Cholinergic Agents [3,4]
- Muscarinic antagonists
- Oxybutynin (Ditropan®, Ditropan XL®): 5mg po tid or 5-30mg qd, or patch (Oxytrol®) 2x/wk
- Patch form of oxybutynin may have less dry mouth but is probably not as effective as po
- Tolterodine (Detrol®, Detrol LA®): 2mg po bid or long acting 2-4mg po qd
- Propanthine (Pro-banthine®), hyoscyamine (Cystospaz M®), falvoxate (Urispas®) also
- Side effects include dry mouth, xerophthalmia, dyspepsia, constipation
- Side effects occur significantly less frequently with tolterodine than with oxybutynin
C. Flaccid Type
- Lower Motor Neuron Damage
- Peripheral Neuropathy
- Cauda equina lesion
- Diabetes mellitus
- Multiple sclerosis with spinal lesions
- Symptoms
- Large post-void residual
- Sensation relatively preserved
- Frequent urinary tract infections
- This increases overflow urgency and frequency
- Treatment
- Cholinergics (urocholine, Bethanechol®)
- Intermittent Catheterization
- alpha-1 adrenergic blockers are also helpful (terazosin or tamsulosin (Flomax®))
- Bladder myoplasty (skeletal muscle transplant) was very effective in 3 of 3 patients [2]
D. Sensory (Overflow) Type
- Unable to feel need to void
- Symptoms
- Large Post-Void Residual
- Overflow Incontinence
- Usually associated with Diabetes Mellitus
- Treatment
- Habit training to void periodically b. Cholinergics to increase squeeze may also be helpful
- May require self-catheterizations
E. Disinhibited Type
- Poor Voluntary inhibition of inappropriate voiding
- Reflexive Function otherwise normal
- Usually due to frontal lobe involvement in diffuse cortical lesions or hydrocephalus
- Rule out treatable causes
References
- Andrews KL and Husmann DA. 1997. Mayo Clin Proc. 72(12):1176
- Stenzl A, Ninkovic M, Kolle D, et al. 1998. Lancet. 351(9114):1483
- Tolterodine. 1998. Med Let. 40(1038):101
- Oxybutynin Transdermal. 2003. Med Let. 45(1156):38